Successful surgical resection of lung cancer arising in a transplanted lung, using venovenous extracorporeal membrane oxygenation to overcome the challenge of single-lung ventilation during the procedure.
A patient with small-cell lung cancer developed type 1 diabetes many weeks after receiving serplulimab, highlighting the need for continued monitoring of blood glucose levels and early signs and symptoms of diabetes.
EGFR–tyrosine kinase inhibitors should always be considered for the treatment of advanced NSCLC with atypical EGFR mutations. The currently known efficacy and safety data for the various agents are summarized.
A rare case of pleural recurrence of a high-grade thymic mucoepidermoid carcinoma 21 years after complete resection. The tumor was discovered incidentally and the patient, who remains asymptomatic, is being followed up without intervention for now.
The therapeutic landscape of malignant pleural mesothelioma is rapidly evolving. This review provides an overview of the current treatment strategies and recent therapeutic advances.
Phase 3 findings have shown a significant improvement in the survival of people with advanced pleural mesothelioma with the addition of pembrolizumab to chemotherapy.
Exposure to asbestos is associated with various pathologies, such as asbestosis, mesothelioma, and pleural plaques. As treatment for these disorders is not curative, the main aim should be to limit exposure.
Recent advances in the molecular knowledge of small-cell lung cancer are outlined, as are promising new treatment strategies, including those targeting the DNA damage pathway, oncogenic drivers, and epigenetics.
An exploration of the potential impact of hormone replacement therapy in women on the most commonly occurring lung diseases, such as asthma, lung cancer, and pulmonary hypertension.
Although guidelines recommend the use of tyrosine kinase inhibitors in broad groups of patients with driver mutation-positive NSCLC, this case series points to the need for further research into their efficacy in those with performance status 4.
A discussion of lung microbiome dysbiosis in various chronic respiratory disorders and the mechanisms by which these bacteria can cause or contribute to the severity of disease.
TARGET-TP trial findings support a biomarker-driven, risk-directed approach to thromboprophylaxis in ambulatory patients with gastrointestinal or lung cancer receiving anticancer therapy.
A review of the latest findings pertaining to endobronchial ultrasound and lung cancer staging, with an aim to equip clinicians with evidence-based recommendations and highlight avenues for further research.
A meta-analysis has shown that cutaneous immune-related adverse events are prognostic for improved survival among people with cancer receiving immune checkpoint inhibitor therapy.
Treatment with afatinib resulted in durable response in a heavily pretreated patient with advanced lung adenocarcinoma harboring a novel NPTN–NRG1 fusion.
Recurrence of autoimmune hemolytic anemia in a patient receiving pembrolizumab for lung cancer highlights the need to carefully consider the risk–benefit profile of immune checkpoint inhibitors in individuals with pre-existing autoimmune conditions.
Liquid biopsy has shown considerable promise for cancer diagnosis, prognosis, and monitoring of response and recurrence. This review discusses the strengths and current limitations of the approach in the management of cancer.
DLL3 is an attractive therapeutic target in small-cell lung cancer and several targeted agents are under development, such as antibody–drug conjugates, T-cell engager molecules, and CAR T-cell therapies.
